Novo Nordisk plans to test cholesterol-lowering oral solution in phase II trial

In a new phase II trial, Novo Nordisk plans to test the company's cholesterol-lowering PCSK9i inhibitor. As a different feature from the phase I trial, the drug will be tested as an oral treatment.
Photo: Tidsvilde Stine/Ritzau Scanpix
Photo: Tidsvilde Stine/Ritzau Scanpix

This month, Novo Nordisk has initiated a phase II trial with the firm's cholesterol-lowering PCSK9i inhibitor, according to the Danish pharmaceutical firm's Q2 report, published on Wednesday afternoon.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading